A Phase 3 interventional study of Pirtobrutinib and Bendamustine in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Loxo Oncology, Inc.. Active, not recruiting at 108 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, reaches primary completion later than 1 of the 18 other live ones, and was the 5th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Nurix Therapeutics, Inc. · Sites in United States
Ages 18+
Jennifer Woyach · Sites in United States
Ages 75+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 6 · Phase 4 3
First in 2019; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 282 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 87 across the 23 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Loxo Oncology, Inc., one of the names counted as Eli Lilly and Company. Under that name alone:
Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company: 5 open now, 9 under way, 4 of them phase 3. Of 3 finished, 1 (33%) have results posted.
Among the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2021, is one of 4 in phase 3, and was the 5th registered.
Eli Lilly and Company’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2019.
3 of the studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06466122Kerry RogersPirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | 2026-12-31 |
| NCT06333262Inhye AhnFixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Eli Lilly and Company’s 13 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with the following :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity.
Drug: Pirtobrutinib
Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD).
Drug: Bendamustine · Drug: Rituximab
Oral
Also known as: LOXO-305, LY3527727
IV
Also known as: Treanda, Treakisym, Ribomustin, Levact
IV
Also known as: Rituxan, MabThera, Truxima, Riabni, Ruxience
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)
PFS, as assessed by IRC, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.
Time frame: From randomization until documented disease progression or death (up to 40 months)
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Investigator
PFS, as assessed by investigator, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.
Time frame: From randomization until documented disease progression or death (up to 40 months)
To Evaluate the Effectiveness of Arm A Compared to Arm B: Overall Survival (OS)
Assessments of effectiveness include OS, assessed by investigator
Time frame: Up to approximately 5 years
Arm A Compared to Arm B: Time to Next Treatment (TTNT), Assessed by Investigator
TTNT is defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) including the first dose date of pirtobrutinib for Arm B participants who crossed over to receive pirtobrutinib if applicable or death due to any cause, whichever occurs first.
Time frame: From randomization until initiation of the subsequent anticancer therapy or death (up to 41 months)
Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by IRC
ORR, as assessed by IRC, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.
Time frame: From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by Investigator
ORR, as assessed by investigator, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.
Time frame: From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
Arm A Compared to Arm B: Duration of Response (DOR), Assessed by IRC
DoR, as assessed by IRC, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first.
Time frame: From first documented response until the first documented disease progression or death (up to 35 months)
Arm A Compared to Arm B: Duration of Response (DOR), Assessed by Investigator
DoR, as assessed by investigator, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first.
Time frame: From first documented response until the first documented disease progression or death (up to 35 months)
Arm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58
A measure of CLL/SLL-related symptoms (CLL/SLL-related Symptoms score) was derived from 13 items: appetite loss, fatigue (3 items), pain, nausea, dyspnea, and insomnia from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), and night sweats, fever/chills, and fatigue (3 items) from selected items of the EORTC Item Library set 58 (IL-58). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing worse symptoms. TTW of CLL/SLL-related symptoms was defined as the time from randomization to the earliest date of the first sustained worsening in its score from baseline, meeting or exceeding the meaningful within-person change (MWPC) threshold of +5.12 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.
Time frame: From randomization up to 37 months
Arm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30
Physical Functioning was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) Physical Function (PF) scale consisting of 5 items to measure the impact of the disease and its treatment on a participant's ability to perform everyday physical activities, calculated from responses to the five items, each scored on a 4 point scale (1 = not at all to 4 = very much). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing better functioning. TTW of PF was defined as the time from randomization to the earliest date of the first sustained worsening from baseline, with a decline in the meaningful within-person change (MWPC) threshold of -13.33 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.
Time frame: From randomization up to 37 months
Arm A Compared to Arm B: Overall Survival, Assessed by Investigator
Overall survival (OS) is defined as the time from randomization until death from any cause. A descriptive analysis of OS was pre-specified based on the primary endpoint data cutoff.
Time frame: From randomization until death from any cause (up to 41 months)
| Milestone | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Started | 141 | 141 |
| Received at least one dose of study drug (including a partial dose) | 140 | 132 |
| Arm b participants who crossed over to receive pirtobrutinib | 0 | 18 |
| Completed | 0 | 0 |
| Not completed | 141 | 141 |
| Withdrew: On study | 130 | 108 |
| Withdrew: Death | 3 | 10 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal of consent | 5 | 19 |
| Withdrew: Sponsor decision | 2 | 0 |
| Withdrew: Participant did not agree to full active follow-up visits | 1 | 1 |
| Withdrew: Participant denied doing more than one computerized axial tomography test per year | 0 | 1 |
PFS, as assessed by IRC, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.
| Months | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC) | NA (NA to NA) | 33.54 (32.72 to NA) |
PFS, as assessed by investigator, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.
| Months | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Investigator | NA (35.19 to NA) | NA (33.38 to NA) |
Assessments of effectiveness include OS, assessed by investigator
Results for this outcome have not been posted.
TTNT is defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) including the first dose date of pirtobrutinib for Arm B participants who crossed over to receive pirtobrutinib if applicable or death due to any cause, whichever occurs first.
| Months | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Time to Next Treatment (TTNT), Assessed by Investigator | NA (NA to NA) | NA (NA to NA) |
ORR, as assessed by IRC, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.
| Percentage of participants | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by IRC | 94.3 (89.13 to 97.52) | 80.9 (73.38 to 86.99) |
ORR, as assessed by investigator, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.
| Percentage of participants | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by Investigator | 94.3 (89.13 to 97.52) | 82.3 (74.95 to 88.18) |
DoR, as assessed by IRC, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first.
| Months | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Duration of Response (DOR), Assessed by IRC | NA (NA to NA) | 29.86 (28.32 to NA) |
DoR, as assessed by investigator, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first.
| Months | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Duration of Response (DOR), Assessed by Investigator | NA (31.21 to NA) | NA (29.86 to NA) |
A measure of CLL/SLL-related symptoms (CLL/SLL-related Symptoms score) was derived from 13 items: appetite loss, fatigue (3 items), pain, nausea, dyspnea, and insomnia from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), and night sweats, fever/chills, and fatigue (3 items) from selected items of the EORTC Item Library set 58 (IL-58). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing worse symptoms. TTW of CLL/SLL-related symptoms was defined as the time from randomization to the earliest date of the first sustained worsening in its score from baseline, meeting or exceeding the meaningful within-person change (MWPC) threshold of +5.12 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.
| Months | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58 | NA (NA to NA) | NA (NA to NA) |
Physical Functioning was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) Physical Function (PF) scale consisting of 5 items to measure the impact of the disease and its treatment on a participant's ability to perform everyday physical activities, calculated from responses to the five items, each scored on a 4 point scale (1 = not at all to 4 = very much). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing better functioning. TTW of PF was defined as the time from randomization to the earliest date of the first sustained worsening from baseline, with a decline in the meaningful within-person change (MWPC) threshold of -13.33 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.
| Months | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30 | NA (NA to NA) | NA (33.54 to NA) |
Overall survival (OS) is defined as the time from randomization until death from any cause. A descriptive analysis of OS was pre-specified based on the primary endpoint data cutoff.
| Months | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab |
|---|---|---|
| Arm A Compared to Arm B: Overall Survival, Assessed by Investigator | NA (NA to NA) | NA (NA to NA) |
Collected over From randomization up to 41 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A - Pirtobrutinib | 3/141 (2.1%) | 43/140 (30.7%) | 109/140 (77.9%) |
| Arm B - Bendamustine Plus Rituximab | 10/141 (7.1%) | 41/132 (31.1%) | 111/132 (84.1%) |
| Arm B - Crossover to Pirtobrutinib | 0/18 (0%) | 1/18 (5.6%) | 11/18 (61.1%) |
| Event | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab | Arm B - Crossover to Pirtobrutinib |
|---|---|---|---|
| Respiratory tract infectionInfections and infestations | 1/140 | 0/132 | 1/18 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/140 | 7/132 | 0/18 |
| PneumoniaInfections and infestations | 7/140 | 4/132 | 0/18 |
| AnaemiaBlood and lymphatic system disorders | 3/140 | 4/132 | 0/18 |
| Covid-19Infections and infestations | 2/140 | 4/132 | 0/18 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/83 | 1/85 | 0/16 |
| Covid-19 pneumoniaInfections and infestations | 0/140 | 3/132 | 0/18 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/140 | 3/132 | 0/18 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/140 | 3/132 | 0/18 |
| InfectionInfections and infestations | 0/140 | 2/132 | 0/18 |
| Event | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab | Arm B - Crossover to Pirtobrutinib |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 17/140 | 55/132 | 0/18 |
| NauseaGastrointestinal disorders | 3/140 | 31/132 | 0/18 |
| Covid-19Infections and infestations | 29/140 | 9/132 | 0/18 |
| PyrexiaGeneral disorders | 12/140 | 25/132 | 0/18 |
| Upper respiratory tract infectionInfections and infestations | 25/140 | 11/132 | 1/18 |
| AnaemiaBlood and lymphatic system disorders | 13/140 | 21/132 | 1/18 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/140 | 18/132 | 0/18 |
| RashSkin and subcutaneous tissue disorders | 15/140 | 18/132 | 0/18 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/140 | 17/132 | 0/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/140 | 1/132 | 0/18 |
All randomized participants
| Age, Categorical(Participants) | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 68 | 57 | 125 |
| >=65 years | 73 | 84 | 157 |
| Sex: Female, Male(Participants) | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| Female | 58 | 51 | 109 |
| Male | 83 | 90 | 173 |
| Ethnicity (NIH/OMB)(Participants) | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 15 | 26 |
| Not Hispanic or Latino | 126 | 122 | 248 |
| Unknown or Not Reported | 4 | 4 | 8 |
| Race (NIH/OMB)(Participants) | Arm A - Pirtobrutinib | Arm B - Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 33 | 31 | 64 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 0 | 1 | 1 |
| White | 104 | 102 | 206 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 1 | 3 | 4 |
Showing the first 100 of 108 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Jul 2025, 45 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 45 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →